Coologics

Coologics is a healthcare company that specializes in innovative, drug-free treatments for vaginal infections, utilizing advanced cooling technology for effective symptom relief. Coologics focuses on developing non-pharmaceutical treatments for vaginal infections. It was founded in Cleveland, US, and has made strategic advancements in its operations. The company secured its latest funding in April 2025, raising USD 3.

000 mn in a Seed round led by Prevail Partners and Dream Ventures, alongside others. The founder's history is not specified, nor are any previous companies mentioned. Coologics specializes in a patented, drug-free treatment for vaginal infections, primarily through its flagship product, Vlisse. This innovative solution employs controlled cooling technology to provide faster and more effective relief from symptoms associated with yeast and bacterial infections.

Designed as a tampon-like device, Vlisse is intended for immediate symptom relief, significantly reducing the need for traditional antibiotics, which often contribute to antibiotic resistance and prolonged recovery times. The company targets a wide array of end users, including women experiencing recurrent infections, pregnant women at risk of preterm birth, and healthcare providers seeking effective alternatives to traditional treatments. Coologics products are marketed primarily in North America, with plans for expansion into additional international markets, catering to a growing customer base concerned with women's health and the efficacy of conventional treatments. Coologics generates revenue primarily through direct-to-consumer sales of its Vlisse product, alongside partnerships with healthcare providers and potential retail outlets.

The transaction structure is designed to facilitate straightforward purchasing options for end-users, ensuring accessibility and convenience. Coologics may implement various pricing strategies, including single purchases and possibly subscription models for ongoing supply needs, providing a flexible purchasing framework for consumers. The emphasis on a clinically proven and patented treatment supports the product's positioning in the market, aligning it with contemporary healthcare demands focused on effective and safe alternatives for vaginal infections. Overall, the company's revenue model is centered on delivering innovative health solutions while establishing strong relationships within both the medical community and the consumer market.

In April 2025, Coologics raised USD 3. 000 mn in Seed funding, which will be utilized to complete clinical trials, submit for FDA approval, and support the market release of its products. The company plans to expand its market presence beyond North America, targeting additional international regions. The recent funding will directly aid these initiatives, allowing Coologics to enhance its product offerings and reach more consumers seeking effective treatments for vaginal infections.